The total number of records retrieved from this search are 8. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_3060	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bladder cancer cell line	Cell lineSW780	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3061	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bladder cancer cell line	Cell lineSW780	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3062	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bladder cancer cell line	Cell lineSW780	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3090	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bladder cancer cell line	Cell lineSW780	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result45% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3091	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bladder cancer cell line	Cell lineSW780	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result15% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3092	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bladder cancer cell line	Cell lineSW780	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3109	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with 5-FC (200mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bladder cancer cell line	Cell lineSW780	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBD62 mice xenograft for Lovo cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to below 100 mm after 50 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3110	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with 5-FC (200mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bladder cancer cell line	Cell lineSW780	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBD62 mice xenograft for Lovo cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to below 100 mm after 50 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628